연세대학교 · Medicine
Jun Yong Choi 교수의 연구실은 항바이러스 및 항진균 제제 개발에 초점을 맞춘 구조 기반 약물 설계를 중심으로 활동하고 있습니다. 특히 SARS-CoV-2 변이체의 면역 회피 메커니즘과 병원성 세균(예: 아나볼라 바쿠렐라) 감염의 치료 전략을 연구하며, 타겟 단백질인 티미딜산 키나제(TMK) 및 사이토퍼틴 CYP51과의 상호작용을 기반으로 새로운 저작용 약물 후보를 도출하고 있습니다. 이는 약물의 세포 내 침투성과 타겟 특이성을 동시에 향상시키는 데 목적이 있습니다.
표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.
Since the COVID-19 pandemic first began in December 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus has continuously evolved with many variants emerging across the world. These variants are categorized as the variant of interest (VOI), variant of concern (VOC), and variant under monitoring (VUM). As of September 15, 2021, there are four SARS-CoV-2 lineages designated as the VOC (alpha, beta, gamma, and delta variants). VOCs have increased transmissibility compared to
A novel coronavirus (severe acute respiratory syndrome-CoV-2) that initially originated from Wuhan, China, in December 2019 has already caused a pandemic. While this novel coronavirus disease (COVID-19) frequently induces mild diseases, it has also generated severe diseases among certain populations, including older-aged individuals with underlying diseases, such as cardiovascular disease and diabetes. As of 31 March 2020, a total of 9786 confirmed cases with COVID-19 have been reported in South
Submitted by Celso Magalhaes (celsomagalhaes@ufrrj.br) on 2019-09-16T15:54:51Z No. of bitstreams: 1 2014 - Welisson da Silva Ferreira.pdf: 5568636 bytes, checksum: b2e63d949960a75fd37bccaecd81d064 (MD5)
Risk factors such as neutropenia and elevated APACHE II scores are found to be associated with higher mortality rates of A. baumannii bacteraemia. Further study is necessary for the determination of optimal strategies for both the prevention and treatment of these infections.
Thymidylate kinase (TMK) is a potential chemotherapeutic target because it is directly involved in the synthesis of an essential component, thymidine triphosphate, in DNA replication. All reported TMK inhibitors are thymidine analogues, which might retard their development as potent therapeutics due to cell permeability and off-target activity against human TMK. A small molecule hit (1, IC(50) = 58 μM), which has reasonable inhibition potency against Pseudomonas aeruginosa TMK (PaTMK), was ident
A new series of 4-aminopyridyl-based lead inhibitors targeting Trypanosoma cruzi CYP51 (TcCYP51) has been developed using structure-based drug design as well as structure-property relationship (SPR) analyses. The screening hit starting point, LP10 (KD ≤ 42 nM; EC50 = 0.65 μM), has been optimized to give the potential leads 14t, 27i, 27q, 27r, and 27t, which have low-nanomolar binding affinity to TcCYP51 and significant activity against T. cruzi amastigotes cultured in human myoblasts (EC50 = 14-
